Warfarin cohort (reference) Apixaban cohort Warfarin cohort (reference) Dabigatran cohort Warfarin cohort (reference) Rivaroxaban cohort
N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD N/Mean %/SD
Sample size 6310 100% 6310 100% 2342 100% 2342 100% 8055 100% 8055 100%
Baseline comorbidity
CHA2DS2 score 2.8 1.3 2.8 1.3 2.6 1.2 2.6 1.2 2.7 1.3 2.7 1.3
CHA2DS2-VASc Score 4.3 1.6 4.3 1.6 4.0 1.6 4.0 1.6 4.2 1.6 4.2 1.6
HAS-BLED score 3.5 1.3 3.5 1.3 3.2 1.3 3.2 1.4 3.4 1.4 3.4 1.4
Bleeding history 1488 23.6% 1520 24.1% 487 20.8% 499 21.3% 1896 23.5% 1934 24.0%
Myocardial infarction 842 13.3% 857 13.6% 284 12.1% 288 12.3% 1048 13.0% 1079 13.4%
Stroke/SE 749 11.9% 757 12.0% 267 11.4% 263 11.2% 971 12.1% 964 12.0%
TIA 390 6.2% 404 6.4% 143 6.1% 136 5.8% 486 6.0% 503 6.2%
Dose of the index prescription
Standard dose* - - 5414 85.8% - - 2018 86.2% - - 6021 74.7%
Low dose† 896 14.2% 324 13.8% 1606 19.9%
Other dose (rivaroxaban 10 mg
and dabigatran 110 mg)		 - - - - - - - - - - 428 5.3%

*Standard dose: 5 mg apixaban twice daily, 150 mg dabigatran twice daily, and 20 mg rivaroxaban once daily (frequency defined by the respective US product labels).2-4
†Low dose: 2.5 mg apixaban twice daily, 75 mg dabigatran twice daily, and 10 or 15 mg rivaroxaban once daily (frequency defined by the respective US product labels)2-4;
428 patients treated with rivaroxaban were prescribed 10 mg rivaroxaban.

1|2|3|4|5|6|7|8